alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
UNPUBLISHED

UNITED STATES COURT OF APPEALS

FOR THE FOURTH CIRCUIT

No. 04-6063

RICKY EMANUEL SELBY,

Plaintiff - Appellant,

versus

BETH HOLCOMB, (Nurse) Health Service

Administrator; M.D. ABDUL JAMALUDEEN; NURSE

SCHULTZ; SHERIFF P. LANTEIGNE; CAPTAIN; NURSE

PRINCE; NURSE BROOKS; NURSE FLETCHER; NURSE

FIANO; NURSE ANDES; NURSE BRULET; LIEUTENANT

RUSSELL; DEPUTY ULRICH; SERGEANT VARGAS;

LIBRARIAN MAPES; LIEUTENANT LEE WILBURN;

SERGEANT DRISCOLL; DEPUTY M. R. KEOGH;

CORPORAL G. M. HILL,

Defendants - Appellees.

Appeal from the United States District Court for the Eastern

District of Virginia, at Norfolk. Robert G. Doumar, Senior

District Judge. (CA-03-520-2)

Submitted: September 15, 2004 Decided: September 28, 2004

Before MICHAEL, MOTZ, and TRAXLER, Circuit Judges.

Affirmed by unpublished per curiam opinion.

Ricky Emanuel Selby, Appellant Pro Se.

Unpublished opinions are not binding precedent in this circuit.

See Local Rule 36(c).
- 2 -

PER CURIAM:

Ricky Emanuel Selby appeals the district court’s order

dismissing his 42 U.S.C. § 1983 (2000) complaint without prejudice

for failure to exhaust administrative remedies. We have reviewed

the record and find no reversible error. Accordingly, we affirm

for the reasons stated by the district court. See Selby v.

Holcomb, No. CA-03-520-2 (E.D. Va. Dec. 16, 2003). We dispense

with oral argument because the facts and legal contentions are

adequately presented in the materials before the court and argument

would not aid the decisional process.

AFFIRMED
W. S., Appellant/Petitioner(s), v. In the Interest of: J. S., Appellee/Respondent(s).

CASE NO.: 2D17-4954

District Court of Appeal of Florida, Second District.

March 7, 2018

**DECISION WITHOUT PUBLISHED OPINION**

Dismissed.
Order entered August 8 , 2016

In The 

## Court of Appeals Fifth District of Texas at Dallas

No. 05
- 16
- 00880
- CR
JONATHAN MATTHEW LEA THERWOOD, Appellant
V. THE STATE OF TEXAS, Appellee On Appeal from t he 194th Judicial District Court

Dallas County, Texas Trial Court Cause No. F15
- 34596
- M



### O RDER On July 26, 2016, the Court received appellant’s pro se notice of appeal and affidavit of indigency. We ORDER the trial court to appoint counsel to represent a ppellant on this appeal.
We further ORDER the trial court to send this Court the order appointing new counsel within
FIFTEEN DAYS of the date of this order.
We DIRECT the Clerk to send copies of this order to the Honorable Ernest White, Presiding Judge, 1 94th Judicial District Court; and the Dallas County District Attorney’s Office.

/s/ LANA MYERS JUSTICE
# United States Court **of Appeals**  **f or the Fifth Circuit** 

**____________** No. 22 - 10526 Summary Calendar

**____________ United States of America,**  Plaintiff
— Appellee **,** versus **Sergio Mendoza -**  **De La Mora,** Defendant
— Appellant **.**

**______________________________** Appeal from the United States District Court for the Northern District of Texas USDC No. 3:21 - CR - 352 - 1

**_________ _____________________**  Before **Wiener, Elrod,** and **Engelhardt,** Circuit Judges **. Per Curiam**  **:** ***** The attorney appointed to represent Sergio Mendoza - De La Mora has moved for leave to withdraw and has filed a brief in accordance with Anders v. California , 386 U.S. 738 (1967), and United States v. Flores , 632 F.3d 229 (5th Cir. 2011). Mendoza - De La Mora has not filed a response. We have reviewed counsel’s brie f and the relevant portions of the record reflected

**_____________________** * This opinion is not designated for publication. See **5th Cir . R.**  47.5. United States Court of Appeals Fifth Circuit 

### FILED March 2, 2023 Lyle W. Cayce Clerk Case: 22-10526 Document: 00516663870 Page: 1 Date Filed: 03/02/2023No. 22 - 10526

2 therein. We concur with counsel’s assessment that the appeal presents no nonfrivolous issue for appellate review. Accordingly, counsel’s motion for leave to withdraw is **GRANTED** , counsel is excused from further responsibilities herein, and the appeal is **DISMISSED** . See **5th Cir. R.**  42.2 . Case: 22-10526 Document: 00516663870 Page: 2 Date Filed: 03/02/2023
Marquis DUFOUR, Appellant, v. CIT BANK, N.A., Appellee.

Case No. 5D17-3086

District Court of Appeal of Florida, Fifth District.

Decision filed April 10, 2018

**DECISION WITHOUT PUBLISHED OPINION**

AFFIRMED.
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Department of Health and Human Services

###### Centers for Disease Control and Prevention

# FOR FURTHER INFORMATION CONTACT:

                        Mikel Walters, Ph.D., Scientific Review Official, National Center for Injury Prevention and Control, CDC, 4770 Buford Highway NE, Mailstop F-63, Atlanta, Georgia 30341, Telephone (404) 639-0913,                         *MWalters@cdc.gov.*

                        The Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, Centers for Disease Control and Prevention, has been delegated the authority to sign                         **Federal Register**                         notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.                    

Kalwant Smagh,

Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, Centers for Disease Control and Prevention.

[FR Doc. 2022-02380 Filed 2-3-22; 8:45 am]

BILLING CODE 4163-18-P
Order entered September 26. 2022

In The

Court of Appeals 

Fifth District of Texas at Dallas 

No. 05-22-00465-CR

ROYAL DOUGLAS ROBINSON, Appellant

V.

THE STATE OF TEXAS, Appellee

On Appeal from the 291st Judicial District Court

Dallas County, Texas

Trial Court Cause No. F16-00017-U

ORDER

Before the Court is appellant’s September 21, 2022 pro se motion requesting 

leave to file appellant’s second motion for extension of time to file his brief. By 

order entered September 14, 2022, the Court ordered appellant’s tendered brief 

filed as of that date. Accordingly, we DENY AS MOOT appellant’s motion 

seeking leave to file for a second extension on his brief.

/s/ ROBERT D. BURNS, III

CHIEF JUSTICE
NOT FOR PUBLICATION

UNITED STATES COURT OF APPEALS

FOR THE NINTH CIRCUIT

ROGER QUINN, 

Plaintiff-Appellant, 

 v. 

JOANNE KIBODEAUX, 

Defendant-Appellee.

No. 20-36070 

D.C. No. 1:20-cv-00291-DCN 

MEMORANDUM*

Appeal from the United States District Court

for the District of Idaho

David C. Nye, District Judge, Presiding

Submitted February 17, 2021**

Before: FERNANDEZ, BYBEE and BADE, Circuit Judges.

Roger Quinn appeals pro se from the district court’s judgment dismissing his

42 U.S.C. § 1983 action alleging claims related to a family court proceeding. We 

have jurisdiction under 28 U.S.C. § 1291. We review de novo the application of 

abstention under Younger v. Harris, 401 U.S. 37 (1971). ReadyLink Healthcare, 

* This disposition is not appropriate for publication and is not precedent 

except as provided by Ninth Circuit Rule 36-3.

** The panel unanimously concludes this case is suitable for decision 

without oral argument. See Fed. R. App. P. 34(a)(2).

FILED

FEB 22 2021

MOLLY C. DWYER, CLERK

U.S. COURT OF APPEALS
 2 20-36070 

Inc. v. State Comp. Ins. Fund, 754 F.3d 754, 758 (9th Cir. 2014). We affirm. 

The district court properly dismissed Quinn’s action as barred under the 

Younger abstention doctrine because federal courts are required to abstain from 

interfering with pending state court proceedings where “the federal action would 

have the practical effect of enjoining the state proceedings.” Id. at 758-59 (setting 

forth requirements for Younger abstention in civil cases, and explaining that “the 

date for determining whether Younger applies is the date the federal action is filed” 

(citation and internal quotation marks omitted)); H.C. ex rel. Gordon v. Koppel, 

203 F.3d 610, 612-14 (9th Cir. 2000) (explaining that Younger abstention is 

appropriate where federal action seeks to challenge ongoing state child custody 

proceedings). 

Quinn’s motion for temporary injunction pending appeal (Docket Entry Nos.

9 and 10) is denied. 

AFFIRMED.
IN THE UNITED STATES COURT OF APPEALS

FOR THE FIFTH CIRCUIT

No. 13-11392

Conference Calendar

UNITED STATES OF AMERICA,

Plaintiff-Appellee

v.

JEREMY CLAY WILCOX,

Defendant-Appellant

Appeals from the United States District Court

for the Northern District of Texas

USDC No. 5:13-CR-42-1

Before CLEMENT, PRADO, and ELROD, Circuit Judges.

PER CURIAM:*

The Federal Public Defender appointed to represent Jeremy Clay Wilcox

has moved for leave to withdraw and has filed a brief in accordance with 

Anders v. California, 386 U.S. 738 (1967), and United States v. Flores, 632 F.3d 

229 (5th Cir. 2011). Wilcox has not filed a response. We have reviewed 

counsel’s brief and the relevant portions of the record reflected therein. We 

concur with counsel’s assessment that the appeal presents no nonfrivolous 

* Pursuant to 5TH CIR. R. 47.5, the court has determined that this opinion should not 

be published and is not precedent except under the limited circumstances set forth in 5TH 

CIR. R. 47.5.4.

United States Court of Appeals

Fifth Circuit

FILED

August 29, 2014

Lyle W. Cayce

Clerk

 

 Case: 13-11392 Document: 00512750780 Page: 1 Date Filed: 08/29/2014
No. 13-11392

issue for appellate review. Accordingly, counsel’s motion for leave to withdraw 

is GRANTED, counsel is excused from further responsibilities herein, and the 

APPEAL IS DISMISSED. See 5TH CIR. R. 42.2.

2

 Case: 13-11392 Document: 00512750780 Page: 2 Date Filed: 08/29/2014
August 31, 2016

U.S. Department of T

ransportation Docket Management System 1200 New Jersey Ave., SE Washington, DC 20590

RE: Amendment to Exemption 11426 issued pursuant to Section 333 of the FAA Reform Act and Part 11 of the Federal Aviation Regulations in Regulatory Docket NO. FAA-2015-0173

Dear Sir or Madam:

Alaska Aerial Media LLC. was issued an Exemption numbered 11426 (hereinafter the Exemption) for the purpose of aerial cinematog raphy and videography, as well as implementation of emergency use UAS systems with public entities. Alaska Aerial Media requests an amendment to the exemption to allow for altitude deviation up to 2000ft AGL for use in aerial data collection applications with our aircraft previously approved via our amendments

.

Alaska Aerial Media LLC wishes to operate UAS systems at 2000ft AGL in Class G airspace with the use of LATAS software to mitigate safety concerns by watching manned traffic and UAS traffic while avoiding obstacles or collisions. Alaska Aerial Media currently conducts survey in remote locations in Alaska and is confident that UAS operations can reduce the risk associated with manned aviation. All operations of the additional UAS will be in full compliance with the terms of the Exemption.

Please contact the undersigned should you have any questions concerning this request for amendment to the Exemption.

Sincerely,

Ryan P

. Marlow Alaska Aeria l Media 7960 Upper O Malley Road Anchorage Alaska 99507 T el e : ( 9 07 )-71 7 -97 9 4
```

[Congressional Bills 117th Congress]
[From the U.S. Government Publishing Office]
[H. Con. Res. 64 Enrolled Bill (ENR)]

        H.Con.Res.64
                                     Agreed to December 15, 2021        

                    One Hundred Seventeenth Congress

                                 of the

                        United States of America

                          AT THE FIRST SESSION

           Begun and held at the City of Washington on Monday,
         the fourth day of January, two thousand and twenty-one

                          Concurrent Resolution

    Resolved by the House of Representatives (the Senate concurring), 
That in the enrollment of the bill S. 1605, the Secretary of the Senate 
shall make the following correction: Amend the long title so as to 
read: ``An Act to authorize appropriations for fiscal year 2022 for 
military activities of the Department of Defense, for military 
construction, and for defense activities of the Department of Energy, 
to prescribe military personnel strengths for such fiscal year, and for 
other purposes.''.
Attest:

                                 Clerk of the House of Representatives.

Attest:

                                               Secretary of the Senate.
```
<TABLE> <S> <C>

<PAGE>
<ARTICLE> 5

<S>                                        <C>
<PERIOD-TYPE>                              12-MOS
<FISCAL-YEAR-END>                          DEC-31-1997
<PERIOD-START>                             JAN-01-1997
<PERIOD-END>                               DEC-31-1997
<CASH>                                             145
<SECURITIES>                                         0
<RECEIVABLES>                                        0
<ALLOWANCES>                                         0
<INVENTORY>                                          0
<CURRENT-ASSETS>                                     0
<PP&E>                                               0
<DEPRECIATION>                                       0
<TOTAL-ASSETS>                               2,126,556
<CURRENT-LIABILITIES>                                0
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                             0
<OTHER-SE>                                   2,126,556
<TOTAL-LIABILITY-AND-EQUITY>                 2,126,556
<SALES>                                              0
<TOTAL-REVENUES>                                     0
<CGS>                                                0
<TOTAL-COSTS>                                        0
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                   0
<INCOME-PRETAX>                              6,928,894
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                                  0
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                 6,928,894
<EPS-PRIMARY>                                    82.50
<EPS-DILUTED>                                    82.50


</TABLE>
exv10w37






Exhibit 10.37




Non-Employee Director Compensation Summary



Alseres Pharmaceuticals, Inc.’s (the “Company’s”) non-employee directors currently consist of:
William L.S. Guinness; Robert S. Langer, Jr.; Michael J. Mullen; John T. Preston; Gary E. Frashier;
and Henry Brem.



For the
year ended December 31, 2008, the Company’s non-employee
director compensation was earned as
follows, however, the Company has only paid non-employee director
compensation through June 30, 2008:




	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	Per Board and	 	 
	 	 	 	 	 	 	Committee	 	Annual Fee Per
	 	 	2008 Annual	 	 	 	 
	 	 	Retainer	 	Meeting Fees (1)	 	Committee Chaired
	William L.S. Guinness
	 	$	25,000	 	 	$	2,500	 	 	 	—	 
	Robert S. Langer, Jr.
	 	$	25,000	 	 	$	2,500	 	 	$	10,000	 
	Michael J. Mullen
	 	$	25,000	 	 	$	2,500	 	 	$	20,000	 
	John T. Preston
	 	$	25,000	 	 	$	2,500	 	 	$	20,000	 
	Gary E. Frashier 
	 	$	25,000	 	 	$	2,500	 	 	$	10,000	 
	Henry Brem 
	 	$	25,000	 	 	$	2,500	 	 	 	—	 








 




			
	(1)	 	Board and committee fees are paid on a per meeting basis at $2,500 per meeting.




All non-employee directors are reimbursed for ordinary and reasonable expenses of attending any
board or committee meetings.



Each new non-employee director is automatically granted an option to purchase 25,000 shares of the
Company’s common stock (“New Director Options”) upon initial election or appointment (the
“Automatic Grant Date”). The exercise price of any New Director Options granted shall equal the
fair market value of shares of the Company’s common stock subject thereto on the Automatic Grant
Date. New Director Options immediately vest as to 1/3 of the shares subject to such New Director
Options with the remaining 2/3 of the shares subject to such New Director Option vesting in equal
monthly installments over two years (“New Director Option Vesting”).



Each non-employee director is automatically granted an option to purchase 25,000 shares of the
Company’s common stock each year (“Annual Director Options”). The Annual Director Options are
granted in the fourth quarter of each calendar year (the “Annual Grant Date”). The exercise price
of any Annual Director Options granted shall equal the fair market value of shares of the Company’s
common stock subject thereto on the Annual Grant Date. Annual Director Options vest in equal
monthly installments over two years (“Annual Director Option Vesting”). Newly elected non-employee
directors are eligible to receive the Annual Director Options in the fourth quarter of the second
calendar year of service.
Exhibit 11.1

                        Litchfield Financial Corporation
                        Computation of Earnings Per Share

                                                              Three months ended
                                                          ______________________
                                                                 March 31,
                                                          ______________________
                                                            1997           1996
                                                            ____          ______

    Net income                                           $1,145,000    $ 798,000
                                                         ==========    =========

    Net income per common share                          $      .20    $     .14
                                                         ==========    =========

    Weighted average number of  common
       shares outstanding                                 5,446,679    5,436,149
    Weighted average number of common
      stock equivalents outstanding:
      Stock Option                                          344,990      264,742
                                                         ----------    ---------

    Fully diluted weighted average common
       and common equivalent shares
       outstanding (1)                                    5,791,669    5,700,891
                                                          =========    =========


    (1)  Primary  weighted  average  number of  common  stock  equivalents  were
    5,791,623  for the three months ended March 31, 1997 and  5,637,643  for the
    three months ended March 31, 1996. The difference  between primary and fully
    diluted shares outstanding did not have a material effect on the calculation
    of earnings per share.
<TABLE> <S> <C>

<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM FINANCIAL
STATEMENTS FOR THE YEAR ENDED DECEMBER 31, 1996 AND IS QUALIFIED IN ITS ENTIRETY
BY REFERENCE TO SUCH FINANCIAL STATMENTS.
</LEGEND>

<S>                             <C>
<PERIOD-TYPE>                   YEAR
<FISCAL-YEAR-END>                          DEC-31-1996
<PERIOD-START>                             JAN-01-1996
<PERIOD-END>                               DEC-31-1996
<CASH>                                       1,811,182
<SECURITIES>                                         0
<RECEIVABLES>                                8,799,452
<ALLOWANCES>                                 1,339,000
<INVENTORY>                                 13,188,627
<CURRENT-ASSETS>                            23,915,512
<PP&E>                                      42,801,522
<DEPRECIATION>                              13,499,466
<TOTAL-ASSETS>                              53,633,856
<CURRENT-LIABILITIES>                       14,116,414
<BONDS>                                      9,989,461
<COMMON>                                       146,035
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          6
<OTHER-SE>                                  27,639,223
<TOTAL-LIABILITY-AND-EQUITY>                53,633,856
<SALES>                                     43,855,014
<TOTAL-REVENUES>                            43,855,014
<CGS>                                       31,679,577
<TOTAL-COSTS>                               34,984,369
<OTHER-EXPENSES>                            26,616,427<F1>
<LOSS-PROVISION>                             1,213,808
<INTEREST-EXPENSE>                           1,850,446
<INCOME-PRETAX>                           (20,810,036)
<INCOME-TAX>                                 3,901,000<F2>
<INCOME-CONTINUING>                       (24,711,036)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                              (25,640,507)
<EPS-PRIMARY>                                   (2.44)
<EPS-DILUTED>                                   (2.44)
<FN>
<F1>INCLUDES A ONE-TIME, NON-CASH CHARGE OF $8.6 MILLION FOR THE RECORDING OF
PURCHASE OF IN-PROCESS RESEARCH AND DEVELOPMENT IN CONNECTION WITH THE
COMPANY'S ACQUISITION OF HALLMARK PHARMACEUTICALS, INC.
<F2>THE $3.9 MILLION OF INCOME TAX EXPENSE WAS RECORDED TO RESTORE FULLY THE
VALUATION ALLOWANCE ON THE COMPANY'S DEFERRED TAX ASSETS, IN ACCORDANCE WITH
SFAS 109.
</FN>


</TABLE>